Saturday, January 09, 2016 7:08:17 PM
Finding, Linda told us at the annual meeting, in answer to my question, that they were almost at the total number for full enrollment in DCVaxL. While she didn't come out and say it, she agreed with my comments that they have a three month enrollment pipeline, where patients need to take the standard of care treatment and go through blood draws. She also agreed that a large number of patients end up In the parallel trial because they are rapid professors or pseudo progressors, so they don't end up in the Ph III trial .
It is my personal opinion that they missed by a few patients. If that's the case, they probably have already enrolled those few patients, plus a few more, and we will see enrollment reached 3 months from when they realized they had missed,... Maybe February. And then We will get the PR. I should have asked; I was more than a bit surprised that she acknowledged that they were almost at the total
This is unlikely to change the completion date of the trial by more than a month, if that. And she's already acknowledged that.
It is my personal opinion that they missed by a few patients. If that's the case, they probably have already enrolled those few patients, plus a few more, and we will see enrollment reached 3 months from when they realized they had missed,... Maybe February. And then We will get the PR. I should have asked; I was more than a bit surprised that she acknowledged that they were almost at the total
This is unlikely to change the completion date of the trial by more than a month, if that. And she's already acknowledged that.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
